- The tafamidis meglumine form (20 mg capsule) has been granted Priority Review
- Tafamidis was granted Orphan Drug Designation for ATTR-CM in both the EU and US in 2012
... read more
... read more
Numerate, Inc. announced on 1/7/19 a multi-target research collaboration with Lundbeck Pharmaceutical to identify clinical candidates for the treatment of disorders in the central nervous system,... read more
Atlantic Therapeutics announced on 1/7/19 that it has closed €28 million in Series B funding to continue its rapid growth trajectory.
Having recently gained FDA clearance for its INNOVO® ... read more
Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions announced on 1/4/19 the closing of a $... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,